Kinesiotaping in Trauma (NCT05976256) | Clinical Trial Compass
RecruitingNot Applicable
Kinesiotaping in Trauma
Netherlands387 participantsStarted 2023-12-11
Plain-language summary
Rationale: Patients with acute traumatic injury to the shoulder or chest wall in de Emergency Department (ED) usually have intense pain. The patient normally is treated with oral analgesics as standard care and in shoulder injury with a sling. Pain of the shoulder or chest wall increases with movement of the affected arm and chest. Kinesiotaping is offered regularly as an additional pain treatment, but there is no hard evidence about its effectiveness. A randomized pilot study in OLVG (Bakker 2022) showed the pain decreasing more when using kinesiotaping comparing to no tape. However, a placebo-effect could not be ruled out and the pilot data need confirmation in a large cohort of patients to study the effectiveness of additional treatment with kinesiotaping in terms of pain, comfort and patient satisfaction.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* ≥18 years
* Acute injury (occurred \<24 hours ago)
* Single shoulder or chest wall injury, which includes one of the following injuries:
* rib fracture
* disruption of the AC-joint Tossy type 1 and 2
* not or hardly dislocated fracture of the clavicle
* Not or hardly dislocated fracture of the r proximal humeral fracture
Exclusion Criteria:
* • Patients younger than 18 years
* Incapacitated persons
* Refusal of participation
* Intubation indication
* Decrease of Consciousness
* Hemodynamic instability
* 3 or more rib fractures
* Rib fracture rib 1-3
* Indication for surgery
* Hospitalization required
* Presence of a haemo- or pneumothorax with chest drain indication
* Already known with allergy for adhesive tape
* Patients with very thin or loose skin on the applicable body part
* Skin infection/irritation or open wound on the applicable body part
* Patients who do not speak Dutch or English
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
number of patients with clinically meaningful pain reduction